Search

Search Results

1. Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy

   Purpose

   Fibroblast activation protein (FAP) is a pan-cancer target and now the state-of-the-art to develop radiopharmaceuticals. FAP inhibitors have...

   Yu Liu, Haocheng Tang, ... Zhibo Liu in European Journal of Nuclear Medicine and Molecular Imaging

   Article 27 April 2023
   

2. Locoregional Radionuclide Cancer Therapy Clinical and Scientific Aspects

   This book reviews locoregional radionuclide cancer therapies (LRCT). Proving an increasingly viable alternative to radiotherapy, radionuclide therapy...

   Franklin C.L. Wong

   Book 2021
   

3. Routine first-line detection of breast cancer therapy-related cardiotoxicity by serial, fast and ultra-low-dose equilibrium radionuclide angiography

   Background

   This study assesses a first-line left ventricular ejection fraction (LVEF) monitoring provided by an ultra-low-dose equilibrium...

   Charles-Edouard Decorads, Aurélien Lambert, ... Pierre-Yves Marie in Journal of Nuclear Cardiology

   Article 26 October 2022
   

4. Radionuclide scintigraphy as an ancillary test for death determination in infants under two months of age

   Nicole K. McKinnon, John Basmaji in Canadian Journal of Anesthesia/Journal canadien d'anesthésie

   Article 01 April 2023

5. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

   Purpose

   Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed...

   Dirk Zboralski, Aileen Hoehne, ... Frank Osterkamp in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 24 May 2022
   

6. Radionuclide Imaging of Infection and Inflammation A Pictorial Case-Based Atlas

   This atlas explores the latest advances in radionuclide imaging in the field of inflammatory diseases and infections, which now typically includes...

   Elena Lazzeri, Alberto Signore, ... Giuliano Mariani

   Book 2021
   

7. EANM recommendations based on systematic analysis of small animal radionuclide imaging in inflammatory musculoskeletal diseases

   Inflammatory musculoskeletal diseases represent a group of chronic and disabling conditions that evolve from a complex interplay between genetic and...

   Erik H. J. G. Aarntzen, Edel Noriega-Álvarez, ... Samantha Y. A. Terry in EJNMMI Research

   Article Open access 06 September 2021
   

8. The LUTIA trial: a small step for PRRT, a giant leap for intra-arterial radionuclide therapy trial methodology

   Christophe M. Deroose in European Journal of Nuclear Medicine and Molecular Imaging

   Article 30 December 2023

9. Efficacy and safety of peptide receptor radionuclide therapy with [¹⁷⁷Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma

   Purpose

   There is no evidence-based systemic therapy for patients with progressive meningiomas for whom surgery or external radiotherapy is no longer...

   Noémie S. Minczeles, Eelke M. Bos, ... Tessa Brabander in European Journal of Nuclear Medicine and Molecular Imaging

   Article 01 December 2022
   

10. Semi-automated segmentation methods of SSTR PET for dosimetry prediction in refractory meningioma patients treated by SSTR-targeted peptide receptor radionuclide therapy

    Objectives

    Tumor dosimetry with somatostatin receptor–targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by ¹⁷⁷ Lu-DOTATATE may...

    Caroline Boursier, Timothée Zaragori, ... Antoine Verger in European Radiology

    Article 06 May 2023
    

11. First preclinical evaluation of [²²⁵Ac]Ac-DOTA-JR11 and comparison with [¹⁷⁷Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs

    Background

    The [ ¹⁷⁷ Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to...

    Maryana Handula, Savanne Beekman, ... Yann Seimbille in EJNMMI Radiopharmacy and Chemistry

    Article Open access 30 June 2023
    

12. The challenges of using radionuclide imaging to guide cardiac device implantation in patients with heart failure

    Mark I. Travin in Journal of Nuclear Cardiology

    Article 02 September 2022

13. Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience

    Purpose

    Peptide receptor radionuclide therapy represents a therapeutic option for neuroendocrine neoplasms; to date, experiences with peptide receptor...

    Fabio Minutoli, Davide Cardile, ... Sergio Baldari in Nuclear Medicine and Molecular Imaging

    Article 12 January 2021
    

14. Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review

    Purpose

    ¹⁷⁷ Lu- labelled somatostatin analog DOTATATE is an excellent vector for systemic radiation therapy in NETs. However, this treatment can...

    Amit Nautiyal, Sofia Michopoulou, Matt Guy in Clinical and Translational Imaging

    Article 20 September 2023
    

15. Can the promise of radionuclide cardiac innervation imaging be fulfilled?

    Mark I. Travin in Journal of Nuclear Cardiology

    Article 19 January 2022

16. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy

    Purpose

    Peptide receptor radionuclide therapy (PRRT) and somatostatin analogues (SSAs) are commonly combined as primary treatment for neuroendocrine...

    Aleksandra Syguła, Aleksandra Ledwon, ... Daria Handkiewicz-Junak in European Journal of Nuclear Medicine and Molecular Imaging

    Article 03 May 2022
    

17. In vitro and in vivo study on the treatment of non-small cell lung cancer with radionuclide labeled PD-L1 nanobody

    Purpose

    Nanobodies have become promising carriers due to excellent in vivo properties. Radiopharmaceutical therapy targeting programmed cell death...

    Mengqin Zhu, Jiajia Zhang, ... Fei Yu in Journal of Cancer Research and Clinical Oncology

    Article 21 April 2023
    

18. Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy

    Purpose of Review

    Peptide receptor radionuclide therapy (PRRT) with [ ¹⁷⁷ Lu-DOTA ⁰ ,Tyr ³ ] octreotate is an effective and safe second- or third-line...

    N.S. Minczeles, J. Hofland, ... T. Brabander in Current Oncology Reports

    Article Open access 15 March 2021
    

19. ASNC Imaging Indications (ASNC-I²): Multisocietal indications for radionuclide imaging in the multimodality context—Series rationale and methodology

    Background

    Appropriate use criteria (AUC) enhance application of cardiovascular imaging techniques but have been applied in limited settings,...

    Jamieson M. Bourque, Andrew J. Einstein, Sharmila Dorbala in Journal of Nuclear Cardiology

    Article 24 September 2021
    

20. Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer

    Purpose of Review

    Prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) is a promising investigational treatment for...

    Michael Sun, Muhammad Junaid Niaz, ... Scott T. Tagawa in Current Oncology Reports

    Article 29 March 2021